Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis

被引:39
作者
Dempsey, Peter J. [1 ,2 ]
机构
[1] Univ Colorado, Sch Med, Grad Program Cell Biol Stem Cells & Dev Program, Aurora, CO 80045 USA
[2] Univ Colorado, Sch Med, Dept Pediat, Div Gastroenterol Hepatol & Nutr, RC2 Rm 6113,12700 E 19th Ave, Aurora, CO 80045 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH | 2017年 / 1864卷 / 11期
基金
美国国家卫生研究院;
关键词
ADAM10; Notch; Intestinal stem cells; Cell lineage specification; GASTROINTESTINAL STEM-CELLS; LABEL-RETAINING CELLS; COLORECTAL-CANCER; COLON-CANCER; BETA-CATENIN; PROGENITOR CELLS; TUFT CELLS; IN-VIVO; E-CADHERIN; DISINTEGRIN/METALLOPROTEINASE ADAM10;
D O I
10.1016/j.bbamcr.2017.07.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A disintegrin and metalloproteinases (ADAMs) are a family of mSultidomain, membrane-anchored proteases that regulate diverse cellular functions, including cell adhesion, migration, proteolysis and other cell signaling events. Catalytically-active ADAMs act as ectodomain sheddases that proteolytically cleave type I and type II transmembrane proteins and some GPI-anchored proteins from the cellular surface. ADAMs can also modulate other cellular signaling events through a process known as regulated intramembrane proteolysis (RIP). Through their proteolytic activity, ADAMs can rapidly modulate key cell signaling pathways in response to changes in the extracellular environment (e.g. inflammation) and play a central role in coordinating intercellular communication. Dysregulation of these processes through aberrant expression, or sustained ADAM activity, is linked to chronic inflammation, inflammation-associated cancer and tumorigenesis. ADAM10 was the first disintegrin-metalloproteinase demonstrated to have proteolytic activity and is the prototypic ADAM associated with RIP activity (e.g. sequential Notch receptor processing). ADAM10 is abundantly expressed throughout the gastrointestinal tract and during normal intestinal homeostasis ADAM10 regulates many cellular processes associated with intestinal development, cell fate specification and maintenance of intestinal stem cell/progenitor populations. In addition, several signaling pathways that undergo ectodomain shedding by ADAM10 (e.g. Notch, EGFR/ErbB, IL-6/sIL-6R) help control intestinal injury/regenerative responses and may drive intestinal inflammation and colon cancer initiation and progression. Here, I review some of the proposed functions of ADAM10 associated with intestinal crypt homeostasis and tumorigenesis within the gastrointestinal tract in vivo. This article is part of a Special Issue entitled: Proteolysis as a Regulatory Event in Pathophysiology edited by Stefan Rose-John.
引用
收藏
页码:2228 / 2239
页数:12
相关论文
共 146 条
[61]   The Notch ligands, Jagged and Delta, are sequentially processed by α-secretase and presenilin/γ-secretase and release signaling fragments [J].
LaVoie, MJ ;
Selkoe, DJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (36) :34427-34437
[62]   Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas [J].
Leto, Simonetta M. ;
Sassi, Francesco ;
Catalano, Irene ;
Torri, Valter ;
Migliardi, Giorgia ;
Zanella, Eugenia R. ;
Throsby, Mark ;
Bertotti, Andrea ;
Trusolino, Livio .
CLINICAL CANCER RESEARCH, 2015, 21 (24) :5519-5531
[63]   Mouse Label-Retaining Cells Are Molecularly and Functionally Distinct From Reserve Intestinal Stem Cells [J].
Li, Ning ;
Nakauka-Ddamba, Angela ;
Tobias, John ;
Jensen, Shane T. ;
Lengner, Christopher J. .
GASTROENTEROLOGY, 2016, 151 (02) :298-+
[64]   Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells [J].
Liu, Phillip C. C. ;
Liu, Xiangdong ;
Li, Yanlong ;
Covington, Maryanne ;
Wynn, Richard ;
Huber, Reid ;
Hillman, Milton ;
Yang, Gengjie ;
Ellis, Dawn ;
Marando, Cindy ;
Katiyar, Kamna ;
Bradley, Jodi ;
Abremski, Kenneth ;
Stow, Mark ;
Rupar, Mark ;
Zhuo, Jincong ;
Li, Yun-Long ;
Lin, Qiyan ;
Burns, David ;
Xu, Meizhong ;
Zhang, Colin ;
Qian, Ding-Quan ;
He, Chunhong ;
Sharief, Vaqar ;
Weng, Lingkai ;
Agrios, Costas ;
Shi, Eric ;
Metcalf, Brian ;
Newton, Robert ;
Friedman, Steven ;
Yao, Wenqing ;
Scherle, Peggy ;
Hollis, Gregory ;
Burn, Timothy C. .
CANCER BIOLOGY & THERAPY, 2006, 5 (06) :657-664
[65]  
Lo Y. H., 2017, GASTROENTEROLOGY
[66]   Endothelial Cells Promote the Colorectal Cancer Stem Cell Phenotype through a Soluble Form of Jagged-1 [J].
Lu, Jia ;
Ye, Xiangcang ;
Fan, Fan ;
Xia, Ling ;
Bhattacharya, Rajat ;
Bellister, Seth ;
Tozzi, Federico ;
Sceusi, Eric ;
Zhou, Yunfei ;
Tachibana, Isamu ;
Maru, Dipen M. ;
Hawke, David H. ;
Rak, Janusz ;
Mani, Sendurai A. ;
Zweidler-McKay, Patrick ;
Ellis, Lee M. .
CANCER CELL, 2013, 23 (02) :171-185
[67]   ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and, β-catenin translocation [J].
Maretzky, T ;
Reiss, K ;
Ludwig, A ;
Buchholz, J ;
Scholz, F ;
Proksch, E ;
de Strooper, B ;
Hartmann, D ;
Saftig, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (26) :9182-9187
[68]   ADAM10-mediated E-cadherin release is regulated by proinflammatory cytokines and modulates keratinocyte cohesion in eczematous dermatitis [J].
Maretzky, Thorsten ;
Scholz, Felix ;
Koeten, Bente ;
Proksch, Ehrhardt ;
Saftig, Paul ;
Reiss, Karina .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2008, 128 (07) :1737-1746
[69]   Essential Roles of IL-6 Trans-Signaling in Colonic Epithelial Cells, Induced by the IL-6/Soluble-IL-6 Receptor Derived from Lamina Propria Macrophages, on the Development of Colitis-Associated Premalignant Cancer in a Murine Model [J].
Matsumoto, Satoshi ;
Hara, Theko ;
Mitsuyama, Keiichi ;
Yamamoto, Mayuko ;
Tsuruta, Osamu ;
Sata, Michio ;
Scheller, Juergen ;
Rose-John, Stefan ;
Kado, Sho-ichi ;
Takada, Toshihiko .
JOURNAL OF IMMUNOLOGY, 2010, 184 (03) :1543-1551
[70]   Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer [J].
Miller, Miles A. ;
Sullivan, Ryan J. ;
Lauffenburger, Douglas A. .
CLINICAL CANCER RESEARCH, 2017, 23 (03) :623-629